Population pharmacokinetic-pharmacodynamic analysis of benznidazole monotherapy and combination therapy with fosravuconazole in chronic Chagas disease (BENDITA).

This trend remained significant or borderline significant even after excluding the placebo group and the influential subject, with an odds ratio consistently between 0.85 and 0.88 across models per unit increase in Ct ( Table 3 ).

also in 11,409 other papers